Sera Prognostics (SERA) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sera Prognostics (SERA) has outperformed YD Bio (YDES) over the past year, losing 36.3% versus a loss of 67.3%. YD Bio is the larger company by market cap ($420.7 million vs $79.9 million), about 5.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SERA | YDES |
|---|---|---|
| Share price | $2.03 | $5.94 |
| Market cap | $79.89M | $420.74M |
| 1-day change | -2.17% | +1.02% |
| YTD return | -29.83% | -51.76% |
| 1-year return | -36.31% | -67.33% |
| 5-year return | -80.92% | — |
| EPS (TTM) | $-0.67 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.95 | $22.00 |
| 52-week low | $1.56 | $1.70 |
| Distance from 52-week high | -48.73% | -73.00% |
| Average volume | 28.38K | 283.39K |
| Shares outstanding | 38.48M | 70.83M |
| Employees | — | 13 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YD Bio is about 5.3 times larger than Sera Prognostics by market value ($420.74M vs $79.89M).
- SERA has outperformed YDES by 31.0 percentage points over the past year.
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
SERA vs YDES FAQ
Which is bigger, Sera Prognostics or YD Bio?
YD Bio (YDES) is larger, with a market capitalization of $420.74M compared with $79.89M for Sera Prognostics (SERA).
Which stock has performed better over the past year, SERA or YDES?
SERA returned -36.31% over the past 12 months, compared with -67.33% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Sera Prognostics and YD Bio in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.